These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36151140)

  • 1. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.
    Zhang H; Bu C; Peng Z; Li G; Zhou Z; Ding W; Zheng Y; He Y; Hu Z; Pei K; Luo M; Li C
    Leukemia; 2022 Nov; 36(11):2596-2604. PubMed ID: 36151140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia.
    Zhang H; Wang P; Li Z; He Y; Gan W; Jiang H
    Clin Cancer Res; 2021 Jul; 27(13):3549-3555. PubMed ID: 33832948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia.
    Pei K; Xu H; Wang P; Gan W; Hu Z; Su X; Zhang H; He Y
    Cancer Med; 2023 Apr; 12(8):9655-9661. PubMed ID: 37031462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
    Zhao Y; Zhang X; Zhang M; Guo R; Zhang Y; Pu Y; Zhu H; Liu P; Zhang Y; He X; Lyu C; Lyu H; Xiao X; Zhao M
    Ann Hematol; 2024 Mar; 103(3):969-980. PubMed ID: 38214708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia.
    Wang H; Feng S; Zhu Y; Zhang Y; Zhou Z; Nian Z; Lu X; Peng P; Wu S; Zhou L
    Blood Transfus; 2024 Aug; ():. PubMed ID: 39133622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.
    Xie D; Jin X; Sun R; Zhang M; Lu W; Cao X; Guo R; Zhang Y; Zhao M
    Transl Oncol; 2023 Aug; 34():101695. PubMed ID: 37224766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia.
    Jin X; Zhang M; Sun R; Lyu H; Xiao X; Zhang X; Li F; Xie D; Xiong X; Wang J; Lu W; Zhang H; Zhao M
    J Hematol Oncol; 2022 Jul; 15(1):88. PubMed ID: 35799191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia.
    Lin G; Zhang Y; Yu L; Wu D
    Mol Med Rep; 2021 Mar; 23(3):. PubMed ID: 33495835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
    J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
    Wang X; Zhang Y; Xue S
    Ann Hematol; 2024 Jun; 103(6):1843-1857. PubMed ID: 38381173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia].
    Nakazawa Y
    Rinsho Ketsueki; 2022; 63(10):1446-1453. PubMed ID: 36351654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
    Morsy MM; Azzam AY; Elamin O; Elswedy A; Nashwan AJ
    Leuk Res; 2024 May; 140():107498. PubMed ID: 38582045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospect of CAR T-cell therapy in acute myeloid leukemia.
    Badar T; Manna A; Gadd ME; Kharfan-Dabaja MA; Qin H
    Expert Opin Investig Drugs; 2022 Feb; 31(2):211-220. PubMed ID: 35051347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia.
    Zhang H; Gan WT; Hao WG; Wang PF; Li ZY; Chang LJ
    Front Oncol; 2020; 10():685. PubMed ID: 32528876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.